New Approaches
Conference

Harvard Club of New York City –
35 West 44th Street New York, NY
10036
Day 1 on Tobacco Control: Monday, September 18, 2023 at 8:00am-6:00pm
Day 2 on Cannabinoid Research: Tuesday, September 19, 2023 at 8:00am-6:00pm

2023 Event Registration Form

Please complete the application form below to register for the 2nd Annual New Approaches Conference on Monday, September 18th, and Tuesday, September 19th, 2023 at the Harvard Club of New York City. Ticketing and programming details are to be announced. For general questions about the event, including press, speaker, or sponsor opportunities, please contact events@newapproaches.nyc. We look forward to seeing you in 2023!
The event begins in ...
00
days
00
hours
00
minutes
00
seconds

Eight million smokers die globally every year. Alternative nicotine solutions save lives.

Hosted during United Nations week in September 2022, the inaugural New Approaches to Tobacco Control conference aims to examine the science of harm reduction, regulatory approaches, and technological innovations.
This healthcare conference investigates how reducing global dependence on tobacco can meet the United Nations Sustainable Development Goals (SDGs). Specifically, the United Nations has proposed SDG 3 to improve public health, most of which can be addressed by a reduction in tobacco use. As the tobacco industry contributes 84 million metric tons of CO2 emissions annually, a reduction in tobacco cultivation will also contribute to achieving SDG 13 on climate action and SGD 6 on clean water.
The global crisis of 8 million tobacco-related deaths annually and 1 billion projected deaths this century may be prevented by science-based innovations, such as Electronic Nicotine Delivery Systems (ENDS), improved pharmaceutical Nicotine Replacement Therapies (NRTs), and tobacco-free nicotine, among others.  
By integrating perspectives from research, industry, and government, this conference considers tobacco harm reduction as an integral part of tobacco control and a policy option to improve human health and the environment.  

Conference Co-Chairs

Derek Yach, MBChB MPH
Learn more
Derek Yach is currently an independent global health consultant who has focused his career on the holistic advancement of public health around the world. He was the founder and president of the Foundation for a Smoke-Free World and a former Executive Director of the Noncommunicable Diseases and Mental Health at the World Health Organization (WHO) where Dr. Yach led the development of WHO’s Framework Convention on Tobacco Control (FCTC).
Nataliia Toropova
Learn more
Nataliia Toropova is the head of the Healthy Initiatives International Think Tank and a former Program Manager for the World Health Organization (WHO). Previously, she served as an Advocacy Coordinator for Eastern Europe at the Campaign for Tobacco-Free Kids.

Keynote Highlights

Featured Keynote: The Khan Review in a Global Perspective - The UK as Case Study on Tobacco Control
Learn more
Author of the Khan Review, Dr. Javed Khan will be providing insight into his groundbreaking publicly-commissioned Khan Review examining best practices for achieving a smoke-free UK by 2030.  

Speakers

Learn more
​​Dr. Javed Khan OBE is author of the groundbreaking “Khan Review - Making Smoking Obsolete,” examining best practices for a smoke-free UK. He has led the UK's largest children’s charity, Barnardo’s, and serves on several public and private board committees including his role as Chair of the Integrated Care Board of the UK NHS.  Previously, Javed Khan was the chief executive of Victim Support.  He has received honorary doctorate degrees from Birmingham City University as well as the University of Salford, and was appointed Order of The British Empire for services to young people and education. Dr. Khan had received his BSc. in Mathematics from the University of Salford, and is a qualified secondary education teacher.
Dr. Javed Khan, OBE
Author of "The Khan Review - Making Smoking Obsolete"
Learn more
Vivien Azer is a Managing Director and senior research analyst specializing in beverages, tobacco, and cannabis sectors. Vivien is the first senior Wall Street analyst to cover the emerging cannabis sector, resulting in notable global press coverage across media outlets such as CNBC, The Wall Street Journal, The Economist, Barron’s and Forbes. Vivien’s coverage of the tobacco and cannabis sectors earned her industry accolades including a spot on Institutional Investor’s All- America Research Team on several occasions. In 2022, Vivien was selected as one of the most influential names in cannabis on Forbes’ “The Cannabis 42.0” list. She was also named to MJBiz Daily’s list of “20 Women to Watch in 2019” and selected by Business Insider as a “Rising Star of Marijuana Investing.” Prior to joining Cowen and Company in 2014, she spent over nine years at Citi covering consumer staples. Vivien holds a BA from the College of William and Mary and an MBA from NYU’s Stern School of Business.
Vivien Azer
Managing Director, Cowen
Learn more
Jasjit S. Ahluwalia is a physician and public health scientist at Brown University’s Schools of Public Health and Medicine, and is the Associate Director of the Legoretta Cancer Center. He has been in academic medicine since 1992 and has been a practicing physician, faculty member, department chair, associate dean and center director in medical schools, and dean of the School of Public Health. His primary research areas are smoking cessation and nicotine addiction in African American smokers. He has been continuously funded by the National Institutes of Health for 25 years and has published more than 350 manuscripts. Ahluwalia has served on the U.S. government’s National Advisory Council on Minority Health and Health Disparities, on the SRNT board of directors and just completed a 3 year term on the federal government’s Interagency Committee on Smoking and Health chaired by the U.S. Surgeon General. Ahluwalia trained at New York University, received a Doctor of Medicine degree and a Master of Public Health degree at Tulane University, a medical residency at the University of North Carolina at Chapel Hill and a clinical epidemiology fellowship at Harvard Medical School, where he received a master’s degree in health policy.
Dr. Jasjit S. Ahluwalia, MD MPH MS
Professor of Medicine, Professor of Behavioral and Social Sciences, Brown University
Learn more
Jasjit S Ahluwalia, MD, MPH, MS
HIDE
Professor at Brown University School of Public Health
Learn more
Indrani Pal-Chaudhury is a global human rights activist who focuses much of her career on human trafficking and environmental sustainability. She teaches at Princeton University.
Indrani Pal-Chaudhuri
Social Justice Activist and Celebrity Film Maker

Learn more
“Described by Rolling Stone as "the point man" for drug policy reform efforts and “the real drug czar,” Ethan Nadelmann is widely regarded as the outstanding proponent of drug policy reform both in the United States and abroad. He founded and directed first The Lindesmith Center and then the Drug Policy Alliance from 1994 to 2017, during which time he and his colleagues were at the forefront of dozens of successful campaigns to legalize marijuana and advance harm reduction alternatives to the war on drugs.  Ethan currently hosts the leading podcast on all things drugs: PSYCHOACTIVE.”
Dr. Ethan Nadelmann
Co-Founder of the Drug Policy Alliance

Learn more
Sammi Toorish is a highly motivated cannabis enthusiast with a deep passion for science, the cannabis plant, and the people both can serve. Sammi is a Colgate University alumna where her focus on International Relations prompted a dedicated interest in issue-based politics, particularly public health; human rights; economic development; and community empowerment. Sammi has deep experience in private market due diligence, political and non-profit fundraising, and cannabis-specific market research.Sammi joined Arcadian Capital in 2021, focused on portfolio management, deal origination, and due diligence. Prior to Arcadian, Sammi spent 3+ years supporting 30+ top PE and VC firms in and outside of cannabis. Sammi was most recently at BDSA, a leading market research firm to the cannabis industry, helping investors and operators utilize data for better investment and strategic decision-making. Previously, Sammi spend time at VU Venture Partners, leading four early-stage investments across Consumer and Frontier verticals.
Sammi Toorish
VP, Investments - Arcadian Capital

Learn more
Laurent Manca is an innovator, inventor and strategist focused on disrupting mature industries. He holds 40+ US and international patents as the co-inventor of heat-not-burn product IQOS. Previously, Laurent worked at Philip Morris on IQOS as well as multiple other Reduced Risk Products. He is a co-founder of the tobacco-free nicotine vaporizer company SMOOD. SMOOD has grown into a global vaping business built on sustainability, advanced chemistry, and granted and pending hardware patents. Laurent graduated from Ecole Hôtelière de Lausanne (Bachelor), HEC Geneva (MBA), and MIT (FinTech).
Laurent Manca
Inventor of IQOS

Learn more
Tony Abboud is an attorney, government affairs expert, and regulatory consultant who represents companies in the tobacco and vapor spaces and who serves as the executive director of the Vapor Technology Association (VTA).  VTA is a U.S. trade association representing the alternative nicotine products industry. Abboud was instrumental in founding and growing VTA, which advocates for rational science-based regulations and a well-regulated marketplace for lower risk nicotine products as an alternative to cigarettes.  Abboud has extensive experience in law, public policy, government and politics. He has represented companies on legal and regulatory issues for more than 25 years. Abboud left the international law firm Greenberg Traurig, LLP in 2010 to found his consulting firm, Strategic Government Solutions, which focuses on companies and associations in heavily regulated industries, including the tobacco and vapor industries, and has advised such companies for more than a decade.  Abboud is recognized as a leading voice for essential regulations and a balanced discussion of vapor products. He is a frequent speaker at national symposiums and has been extensively quoted in the media, including national print, television and radio.  Tony lives near Chicago with his wife, a former Cook County prosecutor, and their three children.  Tony earned his B.A. in Political Science from Carleton College in 1988 and his J.D. with distinction from the University of Iowa College of Law in 1994.
Tony Abboud
Executive Director, Vapor Technology Association (VTA), President Strategic Government Solutions Inc.



Learn more
Jeannie Cameron is an expert on the WHO Framework Convention on Tobacco Control FCTC, including attending its negotiation in Geneva and the development of its subsequent Protocol on Illicit Trade. As part of an LLM in 2007, Jeannie earned a distinction from King’s College University of London for a dissertation on the topic of Emerging International Public Health Issues – Human Rights, Harm Reduction, and the Framework Convention on Tobacco Control (FCTC). Jeannie has been a parliamentary advisor, chief of staff as well as a civil servant in the International Legal Section of the Australian Cabinet participating in international forums including the Copenhagen World Summit for Social Development and the Beijing UN Platform for Action on Discrimination Against Women. She has consulted for the OECD and served as Co-Chair of the OECD’s Charting Illicit Trade Taskforce on Environmentally Sensitive Goods and Wildlife. Jeannie is CEO of JCIC International, a UK based strategic advocacy consultancy founded in 2011 focused on strategic advocacy. Jeannie has consulted for PMI on various global initiatives and formerly headed BAT’s International Political and Regulatory Affairs area. Jeannie took an 18-month break from consulting in January 2020 to work as Vice President, International at Juul Labs. Jeannie is an active commentator on tobacco harm reduction, public administration and governance reform.
Jeannie Cameron
Legal and Policy Expert

Learn more
Entrepreneur Julien Lacour-Gayet is the CEO of an electronic NRT development company Ventus Medical.  Previously, Lacour-Gayet served as the International Business Developer at Nespresso, and held various senior management roles at Philip Morris. He was founder and CEO of NEXVAP, a global developer of various NRT drug delivery platforms.   Currently, Lacour-Gayet serves on the board of Ventus Medical Ltd, Nexvap SA, and Neia SA.  Lacour-Gayet possesses a scientific background with a B.A.Sc from Ecole Hotelière de Lausanne and an MBA from IMD.
Julien Lacour-Gayet
CEO of Ventus Medical

Learn more
John has a strong background and reputation in the European e-cigarette industry having held senior executive positions in some of the US and Europe’s biggest companies. As managing director of Dyflin Group Consulting, he advises many leading industry analysts, financial institutions and media organisations looking at the vaping and CBD sectors. John is also Director-General and one of the founders of the UKVIA, the UK’s largest vaping Industry association and has advised the UK government All Party Parliamentary Group on Vaping as well as giving evidence before the UK Science & Technology Committee investigation into the Vaping industry, the Australian and Irish Parliaments review on vaping. John regularly appears on national television, radio as well as national and international print media. John is a popular guest speaker at many of the world’s leading conventions.
John Dunne
Director-General UK Vaping Industry Association (UKVIA), Vape & CBD Industry Consultant

Learn more
Patricia I. Kovacevic is a global legal and compliance nicotine and cannabis industry expert. She currently serves as General Counsel, Corporate Secretary and Head of External Affairs at Cryomass Technologies Inc, and advises clients through her own consulting group, RegulationStrategy. Ms. Kovacevic has over twenty years of experience in the highly regulated nicotine, cannabis and cannabidiol industries. Her career includes leading senior legal and regulatory positions at Philip Morris International and Lorillard, among others.  While at Lorillard, in 2012 she was closely involved with the acquisition of blu, at the time the leading vaping company, which was also the first ever acquisition by a tobacco company of a vaping company. Her team also obtained the first-ever premarket authorization for a new tobacco product issued by the U.S. Food and Drug Administration (FDA) under the Tobacco Control Act. At Nicopure Labs as general counsel she spearheaded the litigation challenging the FDA’s so-called “deeming rule.”  Prior to joining Lorillard, Ms. Kovacevic was a partner at Patton Boggs. Her focus includes M&A in highly regulated industries, such as e-cigarette and tobacco, all aspects of nicotine and cannabis regulation in the US and abroad, SOX compliance and all regulatory aspects of marketing/media communications, corporate affairs, criminal investigations, Foreign Corrupt Practices Act, trade sanctions, privacy, and product development and launch. Ms. Kovacevic served on the board of directors of the Vapor Technology Association and on the advisory board of the Global Tobacco & Nicotine Forum. She authored several articles on nicotine regulation and is often invited as a keynote speaker and presenter before global conferences and government agencies. She holds a Juris Doctor degree from Columbia Law School and is admitted to practice in New York, before the United States Tax Court, the United States Court of International Trade and the Supreme Court of the United States of America. She speaks fluently seven languages.
Patricia I. Kovacevic
Global Legal and Compliance Expert

Learn more
Jordan Nof is a Co-founder and Managing Partner at Tusk Venture Partners L.P. and is a member of the firm’s Investment Committee. He has led many of the firm’s investments including Lemonade, Bird, Coinbase, Alma, Sunday, and Wheel. He currently serves on the board of directors of Alma, Sunday, and Wheel.Prior to Tusk Venture Partners, Jordan spent six years as a Director at Blackstone, where he focused on the development of the firm’s corporate venture capital portfolio. During that time, Jordan focused on investing in early-stage technology companies that could accelerate operations across Blackstone and the firm’s underlying portfolio companies.Before joining Blackstone, Jordan spent four years in the institutional investment management division at AllianceBernstein. During that time, he worked with many of the firm’s largest global institutional sub-advisory relationships.Jordan received an M.B.A. from Rollins Graduate School of Business and is a graduate of Florida State University where he received a B.S. in Finance. He is based out of the firm’s New York office.
Jordan Nof
Co-founder and Managing Partner at Tusk Ventures

Learn more
Dr. Raymond Niaura is a psychologist and an expert on tobacco dependence and treatment, as well as substance use and addiction to alcohol. Dr. Niaura researches the biobehavioral substrates of tobacco dependence, including factors that influence adolescent and early adult tobacco use trajectories. He also evaluates behavioral and pharmacological treatments for tobacco cessation, with a particular interest in cessation in disadvantaged population to address public health disparities in tobacco-related burdens of illness and disability.
Dr. Ray Niaura
Professor of Public Health, NYU

Learn more
Dr. William Jackson has a background in chemistry from Imperial College, London, where he obtained his undergraduate degree and PhD in chemistry, followed by postdoctoral research at MIT. After 10 years of medicinal research, Dr. Jackson moved into the generic pharmaceutical industry developing novel processes for existing drugs. For the last 20 years he has operated an independent laboratory with his work spanning several areas for various clients. He had been working closely with Zanoprima for several years prior to becoming an employee in 2021.
Dr. William Jackson
Scientific Expert, Zanoprima Lifesciences



Learn more
Martin Steinbauer is an entrepreneur and investor focused on medical inhalable devices and aerosolization technology. He co-founded the tobacco-free nicotine vaporizer company SMOOD. SMOOD has grown into a global vaping business built on sustainability, advanced chemistry, and granted and pending hardware patents. Prior to SMOOD, Martin was an investment analyst at BlackRock in New York. Martin graduated from Harvard University with a degree in applied mathematics.
Martin Steinbauer
Founder at SMOOD

Learn more
Before Becoming the Co-Founder and President of ANDS. Fadi has reached many milestones in his career, most notably as the GM and Chairman of Philip Morris in Jordan and PAA, global sales strategy at PMI HQ in Switzerland, and the head of commercial deployment in KSA. He also earned well-deserved coveted positions in JUUL labs as the Head of Middle East, Africa & Turkey and the Head of EU Travel Retail. Fadi is an expert in staging, communication, and brand building of Electronic nicotine delivery solutions, from the angles of Harm reduction, regulatory challenges, and product innovation and development.
Fadi Maayta
Co-Founder and President, ANDS

Learn more
Dr. John Oyston is a trained anesthesiologist, qualifying as a specialist in both the UK and Canada who has served as Chief of Anesthesiology four times. He was an Assistant Professor at the University of Toronto as well as a peer assessor for the College of Physicians and Surgeons of Ontario. Dr. Oyston has taught anesthesiology in Rwanda and Ethiopia and founded the organization“Stop Smoking for Safer Surgery” in 2007. He retired from anesthesiology in November 2019 to work on smoking cessation and vaping issues. Dr. Oyston graduated from the University of Newcastle Upon Tyne, UK, with a medical degree and an additional degree in medical research. He writes about tobacco and other issues on a blog at www.johnoyston.com.
Dr. John Oyston
MB BS, BMedSci, FRCA, FRCP(C)

Learn more
Derek Yach is currently an independent global health consultant who has focused his career on the holistic advancement of public health around the world. He was the founder and president of the Foundation for a Smoke-Free World and a former Executive Director of the Noncommunicable Diseases and Mental Health at the World Health Organization (WHO) where Dr. Yach led the development of WHO’s
Dr. William Jackson HIDE
Zanoprima Lifesciences

Scientific Expert

Dr. Javed Khan, OBE
Learn more
​​Dr. Javed Khan OBE is author of the groundbreaking “Khan Review - Making Smoking Obsolete,” examining best practices for a smoke-free UK. He has led the UK's largest children’s charity, Barnardo’s, and serves on several public and private board committees including his role as Chair of the Integrated Care Board of the UK NHS. Previously, Javed Khan was the chief executive of Victim Support. He has received honorary doctorate degrees from Birmingham City University as well as the University of Salford, and was appointed Order of The British Empire for services to young people and education. Dr. Khan had received his BSc. in Mathematics from the University of Salford, and is a qualified secondary education teacher.
Dr. Javed Khan, OBE
Author of "The Khan Review - Making Smoking Obsolete"

Vivien Azer
Learn more
Vivien Azer is a Managing Director and senior research analyst specializing in beverages, tobacco, and cannabis sectors. Vivien is the first senior Wall Street analyst to cover the emerging cannabis sector, resulting in notable global press coverage across media outlets such as CNBC, The Wall Street Journal, The Economist, Barron’s and Forbes. Vivien’s coverage of the tobacco and cannabis sectors earned her industry accolades including a spot on Institutional Investor’s All- America Research Team on several occasions. In 2022, Vivien was selected as one of the most influential names in cannabis on Forbes’ “The Cannabis 42.0” list. She was also named to MJBiz
Vivien Azer
Managing Director, Cowen

Dr. Jasjit S. Ahluwalia, MD MPH MS
Learn more
Jasjit S. Ahluwalia is a physician and public health scientist at Brown University’s Schools of Public Health and Medicine, and is the Associate Director of the Legorreta Cancer Center. He has been in academic medicine since 1992 and has been a practicing physician, faculty member, department chair, associate dean and center director in medical schools, and dean of the School of Public Health. His primary research areas are smoking cessation and nicotine addiction in African American smokers. He has been continuously funded by the National Institutes of Health for 25 years and has published more than 350 manuscripts. Ahluwalia has served on the U.S. government’s National Advisory Council on Minority Health and Health Disparities, on the SRNT board of directors and just completed a 3 year term on the federal government’s Interagency Committee on Smoking and Health chaired by the U.S. Surgeon General. Ahluwalia trained at New York University, received a Doctor of Medicine degree and a Master of Public Health degree at Tulane University, a medical residency at the University of North Carolina at Chapel Hill and a clinical epidemiology fellowship at Harvard Medical School, where he received a master’s degree in health policy.
Dr. Jasjit S. Ahluwalia, MD MPH MS
Professor of Medicine, Professor of Behavioral and Social Sciences, Brown University

Indrani Pal-Chaudhuri
Learn more
Indrani Pal-Chaudhuri is a global human rights and social justice activist, a CNN, Cannes and Tribeca award-winning mythopoeic filmmaker and collaborator with David Bowie, Beyonce, and Lady Gaga. She is currently focused on disruptive techonologies for education and environmental regeneration. She teaches at Princeton University.
Indrani Pal-Chaudhuri
Climate & Social Justice Activist, Celebrity Filmmaker, Princeton University Visiting Lecturer

Dr. Ethan Nadelmann
Learn more
“Described by Rolling Stone as "the point man" for drug policy reform efforts and “the real drug czar,” Ethan Nadelmann is widely regarded as the outstanding proponent of drug policy reform both in the United States and abroad. He founded and directed first The Lindesmith Center and then the Drug Policy Alliance from 1994 to 2017, during which time he and his colleagues were at the forefront of dozens of successful campaigns to legalize marijuana and advance harm reduction alternatives to the war on drugs. Ethan currently hosts the leading podcast on all things drugs: PSYCHOACTIVE.”
Dr. Ethan Nadelmann
Co-Founder of the Drug Policy Alliance

Sammi Toorish
Learn more
Sammi Toorish is a highly motivated cannabis enthusiast with a deep passion for science, the cannabis plant, and the people both can serve. Sammi is a Colgate University alumna where her focus on International Relations prompted a dedicated interest in issue-based politics, particularly public health; human rights; economic development; and community empowerment. Sammi has deep experience in private market due diligence, political and non-profit fundraising, and cannabis-specific market research. Sammi joined Arcadian Capital in 2021, focused on portfolio management, deal origination, and due diligence. Prior to Arcadian, Sammi spent 3+ years supporting 30+ top PE and VC firms in and outside of cannabis. Sammi was most recently at BDSA, a leading market research firm to the cannabis industry, helping investors and operators utilize data for better investment and strategic decision-making. Previously, Sammi spent time at VU Venture Partners, leading four early-stage investments across Consumer and Frontier verticals.
Sammi Toorish
VP of Investments, Arcadian Capital

Laurent Manca
Learn more
Laurent Manca is an innovator, inventor and strategist focused on disrupting mature industries. He holds 40+ US and international patents as the co-inventor of heat-not-burn product IQOS. Previously, Laurent worked at Philip Morris on IQOS as well as multiple other Reduced Risk Products. He is a co-founder of the tobacco-free nicotine vaporizer company SMOOD. SMOOD has grown into a global vaping business built on sustainability, advanced chemistry, and granted and pending hardware patents. Laurent graduated from Ecole Hôtelière de Lausanne (Bachelor), HEC Geneva (MBA), and MIT (FinTech).
Laurent Manca
Co-Inventor of IQOS

Tony Abboud
Learn more
Tony Abboud is an attorney, government affairs expert, and regulatory consultant who represents companies in the tobacco and vapor spaces and who serves as the executive director of the Vapor Technology Association (VTA). VTA is a U.S. trade association representing the alternative nicotine products industry. Abboud was instrumental in founding and growing VTA, which advocates for rational science-based regulations and a well-regulated marketplace for lower risk nicotine products as an alternative to cigarettes. Abboud has extensive experience in law, public policy, government and politics. He has represented companies on legal and regulatory issues for more than 25 years. Abboud left the international law firm Greenberg Traurig, LLP in 2010 to found his consulting firm, Strategic Government Solutions, which focuses on companies and associations in heavily regulated industries, including the tobacco and vapor industries, and has advised such companies for more than a decade. Abboud is recognized as a leading voice for essential regulations and a balanced discussion of vapor products. He is a frequent speaker at national symposiums and has been extensively quoted in the media, including national print, television and radio. Tony lives near Chicago with his wife, a former Cook County prosecutor, and their three children. Tony earned his B.A. in Political Science from Carleton College in 1988 and his J.D. with distinction from the University of Iowa College of Law in 1994.
Tony Abboud
Executive Director, Vapor Technology Association (VTA), President Strategic Government Solutions Inc.

Jeannie Cameron
Learn more
Jeannie Cameron is an expert on the WHO Framework Convention on Tobacco Control FCTC, including attending its negotiation in Geneva and the development of its subsequent Protocol on Illicit Trade. As part of an LLM in 2007, Jeannie earned a distinction from King’s College University of London for a dissertation on the topic of Emerging International Public Health Issues – Human Rights, Harm Reduction, and the Framework Convention on Tobacco Control (FCTC). Jeannie has been a parliamentary advisor, chief of staff as well as a civil servant in the International Legal Section of the Australian Cabinet participating in international forums including the Copenhagen World Summit for Social Development and the Beijing UN Platform for Action on Discrimination Against Women. She has consulted for the OECD and served as Co-Chair of the OECD’s Charting Illicit Trade Taskforce on Environmentally Sensitive Goods and Wildlife. Jeannie is CEO of JCIC International, a UK based strategic advocacy consultancy founded in 2011 focused on strategic advocacy. Jeannie has consulted for PMI on various global initiatives and formerly headed BAT’s International Political and Regulatory Affairs area. Jeannie took an 18-month break from consulting in January 2020 to work as Vice President, International at Juul Labs. Jeannie is an active commentator on tobacco harm reduction, public administration and governance reform.
Jeannie Cameron
Legal and Policy Expert

Julien Lacour-Gayet
Learn more
Entrepreneur Julien Lacour-Gayet is the CEO of an electronic NRT development company Ventus Medical. Previously, Lacour-Gayet served as the International Business Developer at Nespresso, and held various senior management roles at Philip Morris. He was founder and CEO of NEXVAP, a global developer of various NRT drug delivery platforms. Currently, Lacour-Gayet serves on the board of Ventus Medical Ltd, Nexvap SA, and Neia SA. Lacour-Gayet possesses a scientific background with a B.A.Sc from Ecole Hotelière de Lausanne and an MBA from IMD.
Julien Lacour-Gayet
CEO of Ventus Medical

Patricia I. Kovacevic
Learn more
Patricia I. Kovacevic is a global legal and compliance nicotine and cannabis industry expert. She currently serves as General Counsel, Corporate Secretary and Head of External Affairs at Cryomass Technologies Inc, and advises clients through her own consulting group, RegulationStrategy. Ms. Kovacevic has over twenty years of experience in the highly regulated nicotine, cannabis and cannabidiol industries. Her career includes leading senior legal and regulatory positions at Philip Morris International and Lorillard, among others. While at Lorillard, in 2012 she was closely involved with the acquisition of blu, at the time the leading vaping company, which was also the first ever acquisition by a tobacco company of a vaping company. Her team also obtained the first-ever premarket authorization for a new tobacco product issued by the U.S. Food and Drug Administration (FDA) under the Tobacco Control Act. At Nicopure Labs as general counsel she spearheaded the litigation challenging the FDA’s so-called “deeming rule.” Prior to joining Lorillard, Ms. Kovacevic was a partner at Patton Boggs. Her focus includes M&A in highly regulated industries, such as e-cigarette and tobacco, all aspects of nicotine and cannabis regulation in the US and abroad, SOX compliance and all regulatory aspects of marketing/media communications, corporate affairs, criminal investigations, Foreign Corrupt Practices Act, trade sanctions, privacy, and product development and launch. Ms. Kovacevic served on the board of directors of the Vapor Technology Association and on the advisory board of the Global Tobacco & Nicotine Forum. She authored several articles on nicotine regulation and is often invited as a keynote speaker and presenter before global conferences and government agencies. She holds a Juris Doctor degree from Columbia Law School and is admitted to practice in New York, before the United States Tax Court, the United States Court of International Trade and the Supreme Court of the United States of America. She speaks fluently seven languages.
Patricia I. Kovacevic
Global Legal and Compliance Expert

Brittany Kaiser
Learn more
Human rights activist and whistleblower Brittany Kaiser is a globally recognized expert in data protection and legislative reform, having spent most of her career advising governments, companies and campaigns on both policy and strategy. Qualifying her status as an influential and renowned thought leader, Brittny Kaiser is represented by the CAA, has spoken at the United Nations, the European and British Parliaments, the G20, and WebSummit, as well as guest lecturing at Universities such as Harvard, Oxford and Columbia. She is a best-selling author of Targeted, published globally by Harper Collins, and is the main subject of Emmy-nominated documentary “The Great Hack,” both works relating to her experience as a whistleblower during her time as Director of Program Development at Cambridge Analytica. She has led the Own Your Data Foundation, focusing on training governments, corporate entities as well as families in digital literacy, and also assists in legislative drafting and lobbying for laws that protect individual rights. Brittany Kaiser holds an undergraduate and (MA) with honors in International Relations from the University of Edinburgh, an (LLM) in International Human Rights Law from the University of London Birkbeck College of Law, and an MPhil in International Law from Middlesex University.
Brittany Kaiser
Human Rights Activist and Whistleblower

Jordan Nof
Learn more
Jordan Nof is a Co-founder and Managing Partner at Tusk Venture Partners L.P. and is a member of the firm’s Investment Committee. He has led many of the firm’s investments including Lemonade, Bird, Coinbase, Alma, Sunday, and Wheel. He currently serves on the board of directors of Alma, Sunday, and Wheel.Prior to Tusk Venture Partners, Jordan spent six years as a Director at Blackstone, where he focused on the development of the firm’s corporate venture capital portfolio. During that time, Jordan focused on investing in early-stage technology companies that could accelerate operations across Blackstone and the firm’s underlying portfolio companies.Before joining Blackstone, Jordan spent four years in the institutional investment management division at AllianceBernstein. During that time, he worked with many of the firm’s largest global institutional sub-advisory relationships.Jordan received an M.B.A. from Rollins Graduate School of Business and is a graduate of Florida State University where he received a B.S. in Finance. He is based out of the firm’s New York office.
Jordan Nof
Co-Founder and Managing Partner at Tusk Ventures

Dr. Ray Niaura
Learn more
Dr. Niaura is Professor of Social and Behavioral Sciences and Epidemiology, and Chair of the department of Epidemiology at the School of Global Public Health, New York University. From 2009-2017, he was Director of Research at the Schroeder Institute, Truth Initiative (formerly the Legacy Foundation) in Washington DC. He has extensive expertise in tobacco dependence and treatment, and he has published over 400 peer-reviewed articles and several book chapters in this area. His interests include studying the biobehavioral substrates of tobacco dependence; evaluating behavioral and pharmacological treatments for cessation; and understanding and addressing public health disparities in tobacco-related burdens of illness and disability. He has been Principal Investigator (PI) or co-Investigator of over 70 NIH-funded grants, and he is the former President of the Society of Nicotine and Tobacco Research. He also has a background and interest in factors that influence adolescent/early adult tobacco use trajectories. He was PI of one of the Transdisciplinary Tobacco Use Research Centers (TTURC), and is currently a co-I of a large, multicenter initiative: the Population Assessment of Tobacco and Health Study (PATH, funded by National Institute on Drug Abuse/Center for Tobacco Products, FDA), a national, longitudinal cohort study of more than 40,000 users and non-users of tobacco products ages 12+, including adolescents and young adults.
Dr. Ray Niaura
Professor of Public Health and Chair of Department of Epidemiology, NYU

Dr. William Jackson
Learn more
Dr. William Jackson has a background in chemistry from Imperial College, London, where he obtained his undergraduate degree and PhD in chemistry, followed by postdoctoral research at MIT. After 10 years of medicinal research, Dr. Jackson moved into the generic pharmaceutical industry developing novel processes for existing drugs. For the last 20 years he has operated an independent laboratory with his work spanning several areas for various clients. He had been working closely with Zanoprima for several years prior to becoming an employee in 2021.
Dr. William Jackson
Scientific Expert, Zanoprima Lifesciences

Martin Steinbauer
Learn more

Martin Steinbauer is an entrepreneur and investor focused on medical inhalable devices and aerosolization technology. He co-founded the tobacco-free nicotine vaporizer company SMOOD. SMOOD has grown into a global vaping business built on sustainability, advanced chemistry, and granted and pending hardware patents. Prior to SMOOD, Martin was an investment analyst at BlackRock in New York. Martin graduated from Harvard University with a degree in applied mathematics.

Martin Steinbauer
Inventor of SMOOD

Fadi Maayta
Learn more
Before Becoming the Co-Founder and President of ANDS. Fadi has reached many milestones in his career, most notably as the GM and Chairman of Philip Morris in Jordan and PAA, global sales strategy at PMI HQ in Switzerland, and the head of commercial deployment in KSA. He also earned well-deserved coveted positions in JUUL labs as the Head of Middle East, Africa & Turkey and the Head of EU Travel Retail. Fadi is an expert in staging, communication, and brand building of Electronic nicotine delivery solutions, from the angles of Harm reduction, regulatory challenges, and product innovation and development.
Fadi Maayta
Co-Founder and President, ANDS

Dr. John Oyston, MB BS, BMedSci, FRCA, FRCP(C)
Learn more
Dr. John Oyston is a trained anesthesiologist, qualifying as a specialist in both the UK and Canada who has served as Chief of Anesthesiology four times. He was an Assistant Professor at the University of Toronto as well as a peer assessor for the College of Physicians and Surgeons of Ontario. Dr. Oyston has taught anesthesiology in Rwanda and Ethiopia and founded the organization“Stop Smoking for Safer Surgery” in 2007. He retired from anesthesiology in November 2019 to work on smoking cessation and vaping issues. Dr. Oyston graduated from the University of Newcastle Upon Tyne, UK, with a medical degree and an additional degree in medical research. He writes about tobacco and other issues on a blog at www.johnoyston.com.
Dr. John Oyston, MB BS, BMedSci, FRCA, FRCP(C)
Anesthesiologist, Founder of "Stop Smoking for Safer Surgery" Retired Professor, University of Toronto

Chris Greer
Learn more
Christopher B. Greer (“Chris”) is the current President & CEO of TMA and an expert in regulatory, corporate, government and external affairs. His experience ranges from regulatory strategy, international trade, agency and stakeholder relations, government affairs, corporate governance to communications and trade media. Chris began his career with Verizon Wireless in legal and external affairs. After joining the tobacco industry in 2010, Chris held regulatory and corporate affairs roles in the US, Caribbean, and Central America. In 2017, Chris was appointed TMA President & CEO. TMA is an information source and convener with a strict prohibition on advocacy and over a century of dedication to the collection and dissemination of trade, tax, economic, legal, regulatory, and news data to all tobacco and nicotine stakeholders. TMA’s members and subscribers are diverse; from international, federal, state, and local government agencies, wholesale distributors and importers, major retail chains, laboratories, contract research organizations, peer nonprofits and associations, consultants, financial and law firms, and product manufacturers. Chris resides in the Raleigh, NC area, with his wife, two young sons, and two rambunctious rescue dogs.
Chris Greer
President & CEO, TMA

Maia Stoicovici
Learn more
Maia Stoicovici is an Engineer at SMOOD who focuses much of her work on research and product development of novel inhalable medical devices. Previously, she was an instrumental scientist at L'Oreal USA where she worked on method development for claims substantiation, as well as cosmetic product development. Maia has worked at the Institute of Systems Genetics at NYU Langone automating PCR purification protocols. She owns a small business that focuses on creative content and experiential branding while providing volunteer resources to marginalized communities. Maia holds a B.S. in Chemical and Biomolecular Engineering from NYU.
Maia Stoicovici
Engineer, SMOOD

Kylie Halperin
Learn more
Kylie Halperin is a Co-Founder and serves as Chief Executive Officer at SKYX Group Inc. Kylie co-founded SkyX Group after spending over a decade with world-renowned advertising and marketing firms for fortune 500 companies with a focus on CPG brands such as PepsiCo, Dell, and Revlon. In her most recent role as CEO and Co-Founder of SkyX Group, she established key wholesale relationships with major retailers and defines subsidiary company strategic brand positioning.
Kylie Halperin
CEO and Co-Founder, SKYX Group Inc

John Dunne
Learn more
John has a strong background and reputation in the European e-cigarette industry having held senior executive positions in some of the US and Europe’s biggest companies. As managing director of Dyflin Group Consulting, he advises many leading industry analysts, financial institutions and media organisations looking at the vaping and CBD sectors. John is also Director-General and one of the founders of the UKVIA, the UK’s largest vaping Industry association and has advised the UK government All Party Parliamentary Group on Vaping as well as giving evidence before the UK Science & Technology Committee investigation into the Vaping industry, the Australian and Irish Parliaments review on vaping. John regularly appears on national television, radio as well as national and international print media. John is a popular guest speaker at many of the world’s leading conventions.
John Dunne
Director-General UK Vaping Industry Association (UKVIA), Vape & CBD Industry Consultant

Agenda 2022

8:00 - 8:45 AM
Registration/Breakfast
Learn more
Breakfast, Refreshments and Networking

Harvard Club Entrance/ Harvard Grill
8:45 – 9:00 AM

Welcoming Remarks: To achieve several UN Sustainable Development Goals (SDGs), we must end smoking.
Learn more
The achievement of  SDG 3.4, (reduction of non-communicable disease deaths) is unattainable unless adult smokers are supported to quit or switch to reduced risk nicotine products. In addition, SDGs related to hunger (2),  gender (5), industry innovation (9),inequalities (10), climate action (13), deforestation (15) and partnerships (17) will benefit from accelerated efforts to end smoking. 
Nataliia Toropova
Derek Yach, MBChB MPH
Harvard Hall

Session I: Spotlight on the UK approach and Implications for Other Countries


9:00 - 9:20 AM
Keynote: The Khan Review in a Global Perspective - The UK as Case Study on Tobacco Control
Learn more
This keynote will highlight the central findings of Dr. Javed Khan's independent report commissioned by the UK Government to help end smoking in the UK by 2030.
Dr. Javed Khan, OBE
Harvard Hall
9:20 – 9:40 AM

Response to Keynote: The Khan Review - Reflections from a United States-based Physician Scientist
Learn more
Dr. Ahluwalia’s current work on randomized clinical trials of e-cigarettes and nicotine pouches has contributed to the scientific base that smokers unwilling or not able to quit, can switch to these products. Funded by NIH for more than 25 years, his team published the first randomized clinical trial using a 4th generation e-cigarette which found that smokers can successfully fully switch to e-cigarettes, leading to a dramatic reduction in biomarkers compared to those continuing to use combustible cigarettes. His nicotine and tobacco research for the past three decades has contributed to the knowledge base of smoking cessation in vulnerable populations.  He feels strongly that science, not emotions, must inform policy.

Dr. Jasjit Ahluwalia,
MD MPH MS
Harvard Hall
9:40-9:50
Consumer Perspective
Learn more
Brittany Kaiser will deliver a personal perspective on how vaping helped her quit cigarettes, and improve her life.
Brittany Kaiser, Vaper and Human Rights Activist
Harvard Hall
9:50 - 10:00 AM
Response to Keynote: The Khan Review - Middle Eastern Perspective

Learn more
Fadi Maayta will share a high-level perspective about regulatory and fiscal treatment in the Middle East and North Africa for nicotine delivery solutions and NGPs, highlighting the progress on Harm reduction and illicit trade for this region. Pointing out the importance of having reasonable fiscal and regulatory frameworks for these products as a pathway to allow smokers to phase out from conventional cigarettes while at the same time calling for stricter measures to protect minors and non-smokers. All of these should fall within a collaboration between countries with solid experience in advocating for the ENDS category to replace combustible cigarettes, recognizing the potential to reduce the risk.
Fadi Maayta, Co-Founder and President, ANDS
Harvard Hall
10:00 - 10:30 AM

Panel Discussion: How Can the Best Practices from the UK and the US FDA be Globalized to End Smoking in All Countries?
Learn more
This panel will feature roundtable discussion on FDA authorizations of vaporizers in 2022, prescription vaporizers as a standard of care vs NRTs in the UK, inclusions of vaporizers in essential drug lists, and other health indications such as COPD in heavy cigarette smokers where vaporizers may be groundbreaking.
Dr. Javed Khan, OBE
Dr. Jasjit Ahluwalia, MD MPH MS
Brittany Kaiser, Vaper and Human Rights Activist
Fadi Maayta, Co-Founder and President, ANDS

Moderated by Derek Yach, MBChB MPH
Harvard Hall
10:30 – 10:40 AM

Coffee Break 1
Learn more
Networking, Refreshments and Snacks

Harvard Hall
10:30 - 10:40 AM

Networking
Learn more


Harvard Hall

Session II: Spotlight on Trust in Public Institutions, New Voices, and Human Rights Approaches
10:40 - 10:50 AM

Keynote:  New Voices on SDG 15 (Deforestation) and Reclaiming Land Lost to Tobacco Cultivation
Learn more
The destruction of our ecosystem from forests cleared for tobacco cultivation and by related fires includes a loss in biodiversity, natural disasters from soil erosion, water pollution, and high carbon emissions, disproportionately impacting the most vulnerable women and children of the developing world.  Indrani Pal-Chaudhuri will discuss the role of forest regeneration and education.
Indrani Pal-Chaudhuri, Social Justice Activist and Celebrity Film Maker
Harvard Hall
10:50-11:00
Information Chaos
Learn more

Chris Greer, TMA
Harvard Hall
11:00 – 11:10 AM

Keynote: Lessons from Drug Prohibition & Drug Reform Advocacy
Learn more
The principles underlying tobacco harm reduction (THR) are much the same as those underlying harm reduction with respect to illicit drugs.  The specific challenges, however, differ in important respects.  Ethan Nadelmann draws on his decades of study and advocacy in addressing these issues.
Dr. Ethan Nadelmann,
Co-Founder of Drug Policy Alliance
Harvard Hall
11:10 – 11:20 AM
Keynote: The Right to Health and Tobacco Harm Reduction (THR) as a Human Right
Learn more
To reaffirm the human right to health, over 180 of the world’s governments agreed in a global treaty to protect people from exposure to tobacco smoke, and to nationally implement supply, demand, and harm reduction strategies as tobacco control measures. Jeannie Cameron will discuss this treaty and the human rights obligations it contains and question whether governments are meeting their treaty. obligations with respect to harm reduction strategies.
Jeannie Cameron, Legal and Policy Expert
Harvard Hall
11:20 – 11:30 AM

Keynote: The Researcher’s Role in Engendering Public Trust
Learn more
In the struggle to understand the rapidly changing world around us, from COVID, to climate change, to the opioid epidemic, what is the role of scientists in communicating objective research?  Are conventional scientific processes being misrepresented by special interest groups and the media? What is the role of scientists and researchers in ensuring accurate and honest communication to the layperson?  This keynote will discuss public communications of scientific research, and ways in which the existing information system may be strengthened as it continues to evolve to enrich public trust towards the overall advancement of public health.
Dr. Ray Niaura, Professor of Public Health, NYU
Harvard Hall
11:30 - 11:40 AM
Coffee Break 2
Learn more
Networking, Refreshments and Snacks

Harvard Hall
11:40 – 12:10 PM

Panel: How Building Public Trust as Public Agencies Can Achieve Several SDGs
Learn more
The UN has reported a steady decline in trust in public institutions around the globe, which COVID-19 has only exacerbated.  By examining why tobacco-control matters on a pandemic-like scale, this panel will focus on the responsibility of public leaders to engender institutional trust and why that is crucial to achieving several SDGs, while also assessing the implications that institutional shortfallings may have on democracy and climate change.  
Dr. Ethan Nadelmann, Co-Founder of Drug Policy Alliance
Dr. Ray Niaura, Professor of Public Health, NYU
Dr. John Oyston, Anesthesiologist
Jeannie Cameron, Legal and Policy Expert

Moderated by Tony Abboud, Executive Director VTA, President Strategic Government Solutions Inc.






Harvard Hall
12:10-12:30
Keynote: The Need for a Clear Regulatory Structure
Learn more
An accessible, comprehensive, and attainable regulatory approach to tobacco control promotes and protects public health while providing growth opportunities for innovative companies. This keynote will suggest ways that we can move from subjective interpretive powers of policy makers to a coherent science based approach that places risk proportionate regulation at the core.
Tony Abboud, Executive Director VTA, President Strategic Government Solutions Inc.



Harvard Hall
12:30 – 1:30 PM

Lunch
Learn more
Lunch (served sit down style) and Networking

Biddle Room (3rd Floor)

Session III: Spotlight on New Approaches to Economics and Investment


1:30 – 1:50 PM

Keynote: Reduced Risk Products as an Investment Opportunity
Learn more
This keynote explores the transformation of the tobacco industry from combustion to reduced risk products, inclusive of research and development activity, public market reception/valuations of transformations, and build or buy decisions of incumbents. In particular, how do public markets price reduced-risk products vis-à-vis combustion products in incumbent tobacco companies? How would public markets view companies with only reduced-risk products? What may the total addressable market look like in 5 to 10 years? And how will regulation speed up/slow down these trends in the US and EU?
Vivien Azer, Managing Director, Cowen
Harvard Hall
1:50 – 2:00 PM

Response to Keynote: Venture Capital in Highly-Regulated Industries
Learn more

Jordan Nof, Co-Founder and Managing Partner, Tusk Ventures
Harvard Hall
2:00-2:10
Response to Keynote: Strategic Investments and M&A in Novel Nicotine Products
Learn more
As smoking rates decline, nicotine limits on cigarettes are being debated, and reduced risk products gain market share, tobacco companies and pharmaceutical NRT makers are in need to innovate their product portfolio to stay relevant. This keynote will explore the build or buy decisions by large market players, regulatory obstacles for early stage companies and new products,  and the transformation of the industry as a whole.
Patricia I. Kovacevic, Global Legal and Compliance Expert
Harvard Hall
2:10 – 2:40 PM

Panel Discussion: Where Does Nicotine Fit in an Investor's Portfolio?
Learn more
As the trillion dollar nicotine industry transforms, do investors classify new products as digital health, biotech, consumer, hardware, or other? What are the unique challenges of these categories at various stages, and how can an investor choose likely winners? This panel discussion focuses on investment in public and private companies working in fields of nicotine and highly regulated industries.
Vivien Azer, Managing Director, Cowen
Jordan Nof, Co-Founder and Managing Partner, Tusk Ventures
Sammi Toorish, VP of Investments, Arcadian Capital
Patricia I. Kovacevic, Global Legal and Compliance Expert

Moderated by Martin Steinbauer, SMOOD


Harvard Hall
2:40 – 2:50 PM

Coffee Break 3
Learn more
Networking, Refreshments and Snacks

Harvard Hall

Session IV: Spotlight on New Approaches to Health and Environmental Governance


2:50 - 3:10 PM

Keynote: How to Build a Safe and Sustainable Product for the Modern Consumer
Learn more
As electric vehicles replace combustion motors in cars and electronic nicotine delivery systems phase out combustion delivery methods, a new set of problems arises for difficult-to-recycle consumer e-waste.  In addition to speaking about engineering inspirations from medical devices, consumer electronics, and coffee, this keynote stresses the importance of implementing cradle-to-grave product design for a sustainable and eco-friendly future.
Martin Steinbauer & The SMOOD Brick


Harvard Hall
3:10 – 3:20 PM

Response to Keynote: Building a Medical NRT Inhaler to Move Beyond Smoking
Learn more
While current Nicotine Replacement Therapies (NRT) are medicinally approved and widely available, patients struggle to get acquainted with these unfamiliar delivery systems that require a change of behavior for the purpose of smoking cessation.  As this barrier of adoption exists,  patients’ relapse rates to combustion cigarettes are high. While e-cigarettes may be more familiar, they are not a medicinally approved delivery system and still require patients to vape constantly. Through Ventus Medical’s electronic nicotine replacement therapy, we match the familiar, session based ritual for patients looking to quit combustion tobacco with the safety, quality and efficacy of medicinal cessation treatments. Meet ENHALE.
Julien Lacour-Gayet, CEO of Ventus Medical
Harvard Hall
3:20 – 3:30 PM

Response to Keynote: Nicotine - From Plant to Chemical Plant
Learn more

This keynote will highlight the advantages of synthetic S-nicotine in terms of quality and the environment.
Dr. William Jackson, Scientific Expert, Zanoprima Lifesciences
Harvard Hall
3:30 - 4:00 PM
Panel Discussion: Addressing the Environmental Impact of Consumer Transformation
Learn more
As conventional products innovate and shift into the modern era, new challenges may arise. This panel will discuss industrial progress as it relates to health and sustainability, while also addressing areas of opportunity presented by novel technology.
Indrani Pal-Chaudhuri, Climate & Social Justice Activist, Celebrity Filmmaker
Martin Steinbauer, Inventor of SMOOD
Kylie Halperin, SKYX Group, Co-Founder & CEO
Dr. William Jackson, Scientific Expert, Zanoprima Lifesciences

Moderated by John Dunne, Director-General UK Vaping Industry Association (UKVIA)
Harvard Hall
4:00 – 4:20 PM

Panel Discussion on Innovation (SDG 9): Industry Innovation Leads Away from Combustion -  Bridging Medical and Consumer Devices
Learn more
As the medical industry shifts towards consumer-centric product development, there is much that can be learned from products that qualify under both categories, such as reduced-risk products and ENDS.
Laurent Manca, Inventor of IQOS
Julien Lacour-Gayet, CEO of Ventus Medical
Maia Stoicovici, Chemical Engineer at SMOOD  
Dr. Cother Hajat, Royal College of Physicians

Moderated by Derek Yach, MBChB MPH
Harvard Hall
4:20 - 4:30 PM

Closing Remarks: A Call to Action to Advance the Protection of Public Health
Learn more
..
Derek Yach, MBChB MPH

Harvard Hall
4:30 – 6:00 PM

Networking Reception: Cocktails and Hors d'oeuvres
(Sponsored by SMOOD)

Learn more
Open Bar and Passed
Hors d'oeuvres
Sponsored by SMOOD

Cambridge Room (2nd Floor)
All Day

Private Meeting Rooms Available
Learn more
Rooms on Floor 3 will be available for all to use during the conference.

To reserve a 30-minute slot write your name on the printed bookings sheet located outside each room.


3rd Floor Locations:

Weld Room (8AM-5PM)
Presidents Room (8AM-4:30PM)
Slocum Room (8AM-1PM)
East Room (8AM-10AM)

Harvard Club of New York City

35 West 44th Street New York NY
The 2022 New Approaches on Tobacco Control conference will take place in the Harvard Hall of The Harvard Club of New York, which is conveniently located a few avenues from the United Nations Headquarters. Sign in at the registration desk with your ticket confirmation  to collect your badge and head to the main hall.

About our partners

The following sponsors and partners have made this conference possible and provide valuable perspectives to the conference and networking sessions.

Platinum Sponsor

Learn more
Zanoprima was founded in 2014 to manufacture non-tobacco derived pharmaceutical grade S-nicotine at costs closer to natural tobacco, for a tobacco-free world. After years of research, a novel enzymatic process, utilizing “green chemistry” with significant ESG benefits over extraction procedures enabled full-scale production from October 2021. Process Patents are granted in over 40 countries. A Drug Master File (DMF) and Tobacco Product Master File (TPMF) have been submitted to the US FDA. Using this ultra-pure nicotine, Zanoprima has developed improved  reduced risk nicotine products, including next generation NRT, with patents (filed under PCT) for vaping and oral products.ReplyReply allForwardKH

Learn more
Smokers choose SMOOD® for a cleaner, smoother nicotine experience without tobacco. SMOOD is a consumer vaporizer company built with advanced technology and sustainability programs. Developed by MIT and Harvard medical engineers, SMOOD is transforming the vaping sector by focusing on quality control, safety and reliability.
Learn more
Ventus is a technological company, specialising in innovative nicotine inhalation products.
We are developing the next generation of medical devices. Combining function of ENDS with safety of pharmaceuticals, we are leading the way in manufacturing, regulation and user experience.

Gold Sponsor

Learn more
The principals at Zanicorn have acquired experienced skill sets in the consulting, legal, securities and regulatory sectors. The Zanicorn attorneys and consultants are skilled in working with highly regulated industries such as the tobacco and vaping, pharmaceutical, biotech, cannabis and securities industries and they have worked consistently on standard setting for many government agencies and task forces that formed to set benchmarking standards for these industries. These collective skill sets combined with the genuine attention to detail of a boutique firm allow the principals at Zanicorn to focus a unique cross-section of abilities on client engagements.
Learn more
Inter Scientific provides regulatory consultancy and analytical testing to clients across the globe in the areas of pharmaceutical, cosmetic, vape, food, and medical devices, to ensure that products are safe and meet the legal requirements.   Their services are delivered by experts in their respective fields, with an internationally accredited laboratory integrated with the regulatory services, providing a single-point solution for product compliance.  Inter Scientific are committed to its clients, personnel and the environment, and strive to be a world-class leader in regulatory advice, consultancy, and analytical services.  Inter Scientific are uniquely positioned to unlock global market for their clients.  
Learn more
Demand Vape, the leading B2B distributor of vapor products in the U.S., is committed to sourcing and delivering high quality vapor products to retailers throughout the country and providing the best customer service. Demand Vape’s distribution network and commitment to regulatory compliance is unmatched. The company has played a leading role in the industry’s federal and state regulatory engagement for years. Founded in 2011, today Demand Vape employs over 200 people with high paying jobs in upstate New York.

About the New Approaches to Tobacco Harm Reduction Conference

The conference was founded as a collaboration between public health professionals, tobacco control advocates, public policy experts, and industry participants working on cutting edge research and commercialization of technologies that save lives. Its mission is to bring tobacco harm reduction to the international policy stage as the world moves towards health improvement, sensible regulatory frameworks, and away from combustion tobacco.
Press and General Inquiries Contact
Events@NewApproaches.NYC
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.